Alzamend Neuro announced on May 13, 2025, the initiation of the first of five Phase II clinical studies of AL001. This initial study involves healthy human subjects and is taking place at Massachusetts General Hospital.
The study aims to explore the unique properties of AL001 and its potential to deliver lithium more effectively in the brain compared to marketed lithium salts. This research will serve as a baseline for subsequent trials in patient populations.
This initiation represents a concrete step forward in the clinical development of AL001. The company anticipates that this advancement could enhance the lives of millions suffering from various neuropsychiatric and neurodegenerative conditions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.